AS-248: Prasugrel and Clopidogrel in Chinese CYP2C19 Allelic Variants following Maintenance Doses
Sandra C. Kirkwood(Eli Lilly (United States)), Ronan P. Kelly(Eli Lilly (Singapore)), Mary Ho(Chinese University of Hong Kong), Kathy McCorkle(Eli Lilly (United States)), Lei Shen(Jiangsu University), Nagy A. Farid(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Joseph R. Walker(Daiichi Sankyo (United States)), Guan Koon Ong(Eli Lilly (Singapore)), David S. Small(Eli Lilly (United States)), Mei Teng Loh(Clinical Nutrition Research Centre)
Cited by 2
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
|The Lancet|2009|723
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617